Chemokine Receptor 4 Plays a Key Role in T Cell Recruitment into the Airways of Asthmatic Patients

Vijayanand, Pandurangan; Durkin, Kesta; Hartmann, Guido; Morjaria, Jaymin B.; Seumois, Grégory; Staples, Karl J.; Hall, David A.; Bessant, Christina; Bartholomew, Michelle A; Howarth, Peter H.; Friedmann, Peter S.; Djukanović, Ratko

doi:10.4049/jimmunol.0901342

Cited by 92 publications

(84 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Allergic inflammation, goblet cell hyperplasia, and AHR were only seen in mice reconstituted with PBMCs from atopic donors, and this inflammatory response was abolished by administration of a CCR4 blocking monoclonal antibody (Perros et al, 2009). Further validation of CCR4 as a useful therapeutic target in human asthma has come from Vijayanand et al (2010) who showed that CCR4…”

Section: Ccr4mentioning

confidence: 99%

CC Chemokine Receptors and Chronic Inflammation—Therapeutic Opportunities and Pharmacological Challenges

2013

View full text Add to dashboard Cite

Section: Ccr4mentioning

confidence: 99%

CC Chemokine Receptors and Chronic Inflammation—Therapeutic Opportunities and Pharmacological Challenges

2013

View full text Add to dashboard Cite

“…For disease-related studies, bronchial biopsies can be obtained from individuals with respiratory diseases or healthy control subjects by fiberoptic bronchoscopy, and have been used ex vivo for short term experiments to analyze disease mechanisms. For example, explant models have been used to demonstrate the involvement of T cells in allergic inflammation and to analyze signaling pathways involved in these responses (Hidi et al, 2000;Jaffar et al, 1999;Lordan et al, 2001;Vijayanand et al, 2010). While these models benefit from retaining the normal lung tissue architecture, they are limited by their relatively short term viability, and the barrier properties of the epithelial layer are compromised by exposure of the whole excised tissue sample to challenge agents.…”

Section: Ex Vivo Lung Modelsmentioning

confidence: 99%

Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology

Gordon

Daneshian

Bouwstra

et al. 2015

ALTEX

124

103

View full text Add to dashboard Cite

SummaryModels of the outer epithelia of the human body -namely the skin, the intestine and the lung -have found valid applications in both research and industrial settings as attractive alternatives to animal testing. A variety of approaches to model these barriers are currently employed in such fields, ranging from the utilization of ex vivo tissue to reconstructed in vitro models, and further to chip-based technologies, synthetic membrane systems and, of increasing current interest, in silico modeling approaches. An international group of experts in the field of epithelial barriers was convened from academia, industry and regulatory bodies to present both the current state of the art of non-animal models of the skin, intestinal and pulmonary barriers in their various fields of application, and to discuss research-based, industry-driven and regulatory-relevant future directions for both the development of new models and the refinement of existing test methods. Issues of model relevance and preference, validation and standardization, acceptance, and the need for simplicity versus complexity were focal themes of the discussions. The outcomes of workshop presentations and discussions, in relation to both current status and future directions in the utilization and development of epithelial barrier models, are presented by the attending experts in the current report.

show abstract

“…sCD30 is a soluble form of CD30, which is generated by proteolytic cleavage of the extracellular portion of this transmembrane molecule and can be measured in serum or plasma by enzyme-linked immunosorbent assay (ELISA). Previous reports indicate increasing expression of these factors in patients with Th2 bias status, such as asthma (27), arthritis (7), and lymphoma (2); however, very few reports examine the changes in these Th2 factors in TB patients (16).…”

mentioning

confidence: 99%

Elevated Serum Levels of CCL17 Correlate with Increased Peripheral Blood Platelet Count in Patients with Active Tuberculosis in China

Feng

Yin

Mai

et al. 2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Active tuberculosis (TB) has been associated with imbalance of Th1 and Th2 cytokine pattern. Activation of Th1 lymphocytes, gamma interferon (IFN-␥) production and macrophage activation are crucial in defense against mycobacteria, while Th2 activation and interleukin-4 (IL-4) production are associated with TB progressing and with poor clinical outcome after treatment (6).After being secreted, IFN-␥ and IL-4 are rapidly bound by their receptors and/or inactivated by proteases, which leads to difficulty in detecting these two typical Th1/Th2 cytokines in plasma or serum (26). Therefore, other markers have been investigated as alternative indicators of preferential Th1 or Th2 activity in vivo.CCL17 (thymus and activation-regulated chemokine [TARC]) and CCL22 (macrophage-derived chemokine [MDC]) are two specific chemotactic factors for Th2 cells (12). CD30, a tumor necrosis factor (TNF) receptor II family member, is also correlated with Th2 activation (3). sCD30 is a soluble form of CD30, which is generated by proteolytic cleavage of the extracellular portion of this transmembrane molecule and can be measured in serum or plasma by enzyme-linked immunosorbent assay (ELISA). Previous reports indicate increasing expression of these factors in patients with Th2 bias status, such as asthma (27), arthritis (7), and lymphoma (2); however, very few reports examine the changes in these Th2 factors in TB patients (16).For screening of new Th2 markers in active TB patients, we compared the serum levels of CCL17/TARC, CCL22/MDC, and sCD30 in HIV-negative TB patients with samples obtained from community healthy controls in China. The results indicate that CCL17/TARC and sCD30 might be more suitable as serum Th2 marker than CCL22/MDC in active TB patients. The correlation of these Th2 markers and the platelet and eosinophil counts in peripheral blood were also analyzed. MATERIALS AND METHODSStudy subjects. Peripheral blood was obtained from 103 normal healthy subjects, 101 active pulmonary TB patients, and 18 TB patients in recovery. The age and sex information of patients and controls are presented in Table 1. The patients included were clinically and radiologically diagnosed for pulmonary TB, and diagnoses confirmed by sputum smear and culture for Mycobacterium tuberculosis. The patients were recruited from the clinics of Shanghai Pulmonary Hospital. All of the patients were HIV negative; none of them presented with other infectious diseases or immunosuppressive conditions. All of the active TB patients received anti-TB therapy for less than 1 week and were classified into three categories (5): mild TB was defined by the presence of scattered and nonconfluent pulmonary infiltrates of slight to moderate density in one or both lungs, with the total volume less than one lung, without cavities. Moderate TB was defined by scattered and nonconfluent pulmonary infiltrates present in one or both lungs and/or with dense and confluent lesions but not involving more than one-third of the volume of one lung, with or without cavities with a...

show abstract

Chemokine Receptor 4 Plays a Key Role in T Cell Recruitment into the Airways of Asthmatic Patients

Abstract: Material

Cited by 92 publications

References 31 publications

CC Chemokine Receptors and Chronic Inflammation—Therapeutic Opportunities and Pharmacological Challenges

CC Chemokine Receptors and Chronic Inflammation—Therapeutic Opportunities and Pharmacological Challenges

Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology

Elevated Serum Levels of CCL17 Correlate with Increased Peripheral Blood Platelet Count in Patients with Active Tuberculosis in China

Contact Info

Product

Resources

About